Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative D... (urrentlyavailable. If physicians can in...)

HOME >> BIOLOGY >> TECHNOLOGY

Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics

Date:12/2/2008

urrently available. If physicians can intervene earlier, before the patients suffer debilitation and irreversible damage, the drugs currently used to slow disease progression can be more effective. In addition, the ability to detect Alzheimer's disease processes early and monitor disease progression in the patients' blood will ultimately lead to more effective and personalized treatments."

Helen R. Park, Power3's CEO, said, "This potential agreement will propel the NuroPro(R) diagnostic test to the next level affording the ability to commercialize a physician sought after test for Alzheimer's and Parkinson's Diseases. It is a win/win for both companies."

A final agreement is subject to due diligence investigation and negotiation of a definitive exclusive license and/or acquisition agreement and approval by the Boards of Directors of both companies.

About NuroPro(R)

NuroPro(R) is a test designed to diagnose Alzheimer's, Parkinson's, and Lou Gehrig's disease (ALS) in individuals. The test is based on proteomic technology, in which a blood serum sample is drawn from a patient, and the concentration of selected biomarkers residing in a panel of 59 blood serum protein biomarkers of neurodegenerative disease is monitored and the test determines if a patient has a Neurodegenerative disease, such as Alzheimer's, Parkinson's or Lou Gehrig's Disease (ALS).

About Transgenomic

Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, Cytogenetics automated sy
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
2. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. Transgenomic, Inc. Reports Third Quarter 2008 Results
4. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2008 Earnings Release Conference Call Webcast
5. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
6. Transgenomic Reports Second Quarter 2008 Results
7. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
8. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
9. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
10. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
11. Transgenomic Opens Pharmacogenomics Laboratory in China

Post Your Comments:

Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative D...(urrentlyavailable. If physicians can in...)